Status:
COMPLETED
Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.
Lead Sponsor:
Centre Hospitalier Metropole Savoie
Conditions:
Pre-Eclampsia
HELLP Syndrome
Eligibility:
FEMALE
18+ years
Brief Summary
The pre-eclampsia is a frequent pathology, concerning approximately 5 % of the pregnancies.The pre-eclampsia can evolve into severe maternal and\\or foetal complications and is a major cause of mortal...
Detailed Description
The pre-eclampsia is a frequent pathology, concerning approximately 5 % of the pregnancies. It is a major cause of mortality, mainly in the developing country. His incidence tends to increase in the d...
Eligibility Criteria
Inclusion
- pregnant woman with a diagnosis of placental vascular disease (gestational hypertension, preeclampsia, IUGR)
Exclusion
- patient who refuses the obstetric follow-up
Key Trial Info
Start Date :
January 10 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
233 Patients enrolled
Trial Details
Trial ID
NCT03455387
Start Date
January 10 2017
End Date
December 31 2019
Last Update
June 14 2022
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
CHMetropoleSavoie
Chambéry, Savoie, France, 73000
2
CHU de Brest
Brest, France, 29200
3
Centre Hospitalier Alpes Léman
Contamine-sur-Arve, France, 74130
4
Groupe Hospitalier du Havre
Le Havre, France, 76083